Evidence map›Paper›PMID 39727717›Full record

ReviewCurrent oncology (Toronto, Ont.)2024

Targeting TOP2A in Ovarian Cancer: Biological and Clinical Implications.

Fulvio Borella, Stefano Fucina, Ylenia Seminara, Pietro Denti, Domenico Ferraioli, Luca Bertero, Niccolò Gallio, Jessica Cusato, Giorgio Valabrega, Alberto Revelli and 2 more

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Current oncology (Toronto, Ont.), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Fulvio BorellaGynecology and Obstetrics 1U, Department of Surgical Sciences, University of Turin, 10126 Turin, Italy.ORCID 0000-0001-8398-7557
Stefano FucinaGynecology and Obstetrics 1U, Department of Surgical Sciences, University of Turin, 10126 Turin, Italy.ORCID 0009-0001-2374-7030
Ylenia SeminaraGynecology and Obstetrics 1U, Department of Surgical Sciences, University of Turin, 10126 Turin, Italy.
Pietro DentiGynecology and Obstetrics 1U, Department of Surgical Sciences, University of Turin, 10126 Turin, Italy.
Domenico FerraioliDepartment of Gynecology, Léon Bérard, Comprehensive Cancer Centre, 69008 Lyon, France.
Luca BerteroPathology Unit, Department of Medical Sciences, University of Turin, 10126 Turin, Italy.ORCID 0000-0001-9887-7668
Niccolò GallioGynecology and Obstetrics 2U, Department of Surgical Sciences, University of Turin, 10126 Turin, Italy.ORCID 0000-0002-3041-1201
Jessica CusatoLaboratory of Clinical Pharmacology and Pharmacogenetics, Department of Medical Sciences, University of Turin, 10149 Turin, Italy.ORCID 0000-0003-1977-9694
Giorgio ValabregaDepartment of Oncology, University of Turin, Medical Oncology, Ordine Mauriziano Hospital, 10128 Turin, Italy.ORCID 0000-0001-5444-6305
Alberto RevelliGynecology and Obstetrics 2U, Department of Surgical Sciences, University of Turin, 10126 Turin, Italy.ORCID 0000-0002-5797-3722
Luca MarozioGynecology and Obstetrics 1U, Department of Surgical Sciences, University of Turin, 10126 Turin, Italy.ORCID 0000-0002-9617-5301
Stefano CosmaGynecology and Obstetrics 1U, Department of Surgical Sciences, University of Turin, 10126 Turin, Italy.ORCID 0000-0003-0563-0071

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The enzyme topoisomerase II alpha (TOP2A) plays a critical role in DNA replication and cell proliferation, making it a promising target for cancer therapy. In epithelial ovarian cancer (EOC), TOP2A overexpression is associated with poor prognosis and resistance to conventional treatments. This review explores the biological functions of TOP2A in EOC and discusses its potential as a therapeutic target. We highlight studies on the mechanisms through which TOP2A contributes to tumor progression and recurrence. Additionally, we evaluate the clinical implications of targeting TOP2A, including the use of TOP2A inhibitors and their combination with novel drugs. We provide a comprehensive overview of the current understanding and future directions for targeting TOP2A in the management of EOC.

Indexed as

DNA Topoisomerases, Type IIOvarian NeoplasmsAntigens, NeoplasmCarcinoma, Ovarian EpithelialFemaleHumansMolecular Targeted TherapyPoly-ADP-Ribose Binding ProteinsTopoisomerase II InhibitorsAntigens, NeoplasmDNA Topoisomerases, Type IIPoly-ADP-Ribose Binding ProteinsTOP2A protein, humanTopoisomerase II Inhibitorsanthracyclinesdoxorubicinetoposideimmune checkpoint inhibitorsovarian cancerPARPiTOP2Atopoisomerase

Identifiers

PMID39727717
PMCPMC11674396

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.